Molecular Markers Guiding Thyroid Cancer Management

• Main Authors: Carolina Nylén, Robert Mechera, Isabella Maréchal-Ross, Venessa Tsang, Angela Chou, Anthony J. Gill, Roderick J. Clifton-Bligh, Bruce G. Robinson, Mark S. Sywak, Stan B. Sidhu, Anthony R. Glover
• Format: Article
• Language: English
• Published: MDPI AG 2020-08-01
• Series: Cancers
• Subjects: Genomics; molecular testing; thyroid cancer; surgery; indeterminate nodules; tyrosine kinase inhibitors
• Online Access: https://www.mdpi.com/2072-6694/12/8/2164

The incidence of thyroid cancer is rapidly increasing, mostly due to the overdiagnosis and overtreatment of differentiated thyroid cancer (TC). The increasing use of potent preclinical models, high throughput molecular technologies, and gene expression microarrays have provided a deeper understanding of molecular characteristics in cancer. Hence, molecular markers have become a potent tool also in TC management to distinguish benign from malignant lesions, predict aggressive biology, prognosis, recurrence, as well as for identification of novel therapeutic targets. In differentiated TC, molecular markers are mainly used as an adjunct to guide management of indeterminate nodules on fine needle aspiration biopsies. In contrast, in advanced thyroid cancer, molecular markers enable targeted treatments of affected signalling pathways. Identification of the driver mutation of targetable kinases in advanced TC can select treatment with mutation targeted tyrosine kinase inhibitors (TKI) to slow growth and reverse adverse effects of the mutations, when traditional treatments fail. This review will outline the molecular landscape and discuss the impact of molecular markers on diagnosis, surveillance and treatment of differentiated, poorly differentiated and anaplastic follicular TC.